Some companies give up negotiations to recover Strepto

More pharmaceutical companies are likely to give up if negotiations are unfavorable

Decide that "discontinuance of business is more profitable"

Some pharmaceutical companies with the anti-inflammatory enzyme Streptokinase-streptodornase have conveyed to the NHIS that they are not willing to negotiate.

 

Currently, about five of the 37 pharmaceutical companies subject to negotiation are known to have given up negotiations.

 

However, as the end of the negotiations approaches, more pharmaceutical companies are likely to give up negotiations.

 

According to the industry on the 9th, some pharmaceutical companies of Streptokinase-Streptodornase are giving up negotiations with the NHIS and accepting the deletion of benefits.

 

Last month, the HIRA conducted a re-evaluation of the drug and decided to suspend the evaluation for one year only for items that were agreed to be recovered according to the results of the clinical re-evaluation, although there was no benefit adequacy.

 

The clinical re-evaluation will end next year after submitting a result report.

 

Accordingly, the NHIS is negotiating with pharmaceutical companies to recover salaries according to the results of clinical re-evaluation until the 14th.

 

Pharmaceutical companies that have not reached an agreement in the redemption negotiations will be deleted due to a lack of benefit adequacy depending on the results of the revaluation.

 

Some pharmaceutical companies are believed to have judged that the deletion of benefits is better.

 

This is because if the recovery ratio is high and the clinical revaluation fails, the profit from product sales will also fall significantly.

 

As a result, it is judged that it may be more profitable to close the business at all by deleting benefits.

 

In the ongoing redemption negotiations, the NHIS and pharmaceutical companies are reportedly divided over the redemption rate.

 

The NHIS sticks to more than 20% and pharmaceutical companies to less than 20%.

 

Therefore, some predict that it will be difficult to conclude the negotiations by the deadline of the 14th of this month.

 

Some predict that the delay in negotiations may be more disadvantageous for pharmaceutical companies as the Ministry of Health and Welfare may no longer issue a negotiation order and follow the HIRA opinion that there is no adequacy.

 

As time goes by, there is a high possibility that more pharmaceutical companies will give up negotiations and accept the deletion of benefits.

 

An industry official explained, "If a pharmaceutical company is disadvantaged in the negotiation for a refund, there is a high possibility that the pharmaceutical company with a small sales volume of the drug will choose to give up its business at all." The annual market size of Streptokinase-Streptodornase is about 35 billion won, which is not large.

 

Among them, Hanmi Pharmaceutical's Mucorase and SK Chemicals' Varidase are said to be leading the way, so these pharmaceutical companies are also leading the clinical re-evaluation and negotiations for recovery.